ES529349A0 - Un procedimiento para la preparacion de derivados de acilmorfinano - Google Patents

Un procedimiento para la preparacion de derivados de acilmorfinano

Info

Publication number
ES529349A0
ES529349A0 ES529349A ES529349A ES529349A0 ES 529349 A0 ES529349 A0 ES 529349A0 ES 529349 A ES529349 A ES 529349A ES 529349 A ES529349 A ES 529349A ES 529349 A0 ES529349 A0 ES 529349A0
Authority
ES
Spain
Prior art keywords
acilmorfinan
derivatives
procedure
preparation
acilmorfinan derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES529349A
Other languages
English (en)
Other versions
ES8506635A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of ES8506635A1 publication Critical patent/ES8506635A1/es
Publication of ES529349A0 publication Critical patent/ES529349A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
ES529349A 1981-11-09 1984-02-01 Un procedimiento para la preparacion de derivados de acilmorfinano Granted ES529349A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/319,482 US4374139A (en) 1981-11-09 1981-11-09 Levorotatory N-substituted acylmorphinans useful as analgesic agents

Publications (2)

Publication Number Publication Date
ES8506635A1 ES8506635A1 (es) 1985-08-01
ES529349A0 true ES529349A0 (es) 1985-08-01

Family

ID=23242421

Family Applications (2)

Application Number Title Priority Date Filing Date
ES517222A Expired ES8500948A1 (es) 1981-11-09 1982-11-08 Un procedimiento para la preparacion de derivados de acilmorrfinano.
ES529349A Granted ES529349A0 (es) 1981-11-09 1984-02-01 Un procedimiento para la preparacion de derivados de acilmorfinano

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES517222A Expired ES8500948A1 (es) 1981-11-09 1982-11-08 Un procedimiento para la preparacion de derivados de acilmorrfinano.

Country Status (18)

Country Link
US (1) US4374139A (es)
EP (1) EP0079556A3 (es)
JP (1) JPS5888364A (es)
KR (1) KR840002357A (es)
AU (1) AU9027682A (es)
CA (1) CA1195324A (es)
DK (1) DK491582A (es)
ES (2) ES8500948A1 (es)
FI (1) FI823824A7 (es)
GR (1) GR78317B (es)
HU (1) HU187425B (es)
IL (1) IL67180A0 (es)
MC (1) MC1490A1 (es)
NO (1) NO823707L (es)
NZ (1) NZ202404A (es)
PH (1) PH18458A (es)
PT (1) PT75815B (es)
ZA (1) ZA827905B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423221A (en) * 1982-06-10 1983-12-27 Sisa Pharmaceutical Laboratories, Inc. 7-Carboethoxy-morphinan-6-one compounds
US4454141A (en) * 1982-09-23 1984-06-12 Sisa Pharmaceutical Laboratories, Inc. Trans-B/C-7-(1-hydroxypentyl)-3-methoxy-17 methyl-6,7-didehydromorphinans, and methods of relieving pain with them
EP0184041A1 (en) * 1984-11-13 1986-06-11 Miles Inc. 6-Methylene morphinan purification technique
US4929622A (en) * 1987-09-24 1990-05-29 Hoechst-Roussel Pharmaceuticals, Inc. 2,6-Methanopyrrolo-3-benzazocines
DE4304450A1 (de) * 1993-02-13 1994-08-18 Boehringer Mannheim Gmbh System zur Zubereitung von Flüssigkeiten
EP1359146B1 (en) 2000-10-31 2008-04-09 Rensselaer Polytechnic Institute 4-aryl piperidines as opioid receptor binding agents
AU2002322720B2 (en) 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US20040204862A1 (en) * 2003-04-11 2004-10-14 Wainer Irving W. Computer-based model for identification and characterization for non-competitive inhibitors of nicotinic acetylcholine receptors and related ligand-gated ion channel receptors
CN102379684B (zh) 2005-04-28 2014-11-19 普罗透斯数字保健公司 药物信息系统
KR20090071598A (ko) 2006-09-18 2009-07-01 랩터 파마슈티컬 인코포레이티드 수용체 결합 단백질(ｒａｐ)-접합체 투여에 의한 간 질환의 치료
EP2398500B1 (en) 2009-02-20 2019-03-13 2-BBB Medicines B.V. Glutathione-based drug delivery system
ES2942923T3 (es) 2009-05-06 2023-06-07 Laboratory Skin Care Inc Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas
AU2010326676B2 (en) 2009-12-04 2013-03-14 Alkermes Pharma Ireland Limited Morphinan derivatives for the treatment of drug overdose
JP5964809B2 (ja) 2010-03-22 2016-08-03 レンセラール ポリテクニック インスティチュート オピオイド受容体リガンドとしてのカルボキサミド基を含有するモルヒネ誘導体
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
RS56181B1 (sr) 2011-06-29 2017-11-30 Alkermes Inc Periferno delujuća opioidna jedinjenja
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
WO2014190270A1 (en) 2013-05-24 2014-11-27 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use
US9656961B2 (en) 2013-05-24 2017-05-23 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
WO2018125716A1 (en) * 2017-01-02 2018-07-05 Purdue Pharma L.P. Morphinan derivatives and use thereof
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3723437A (en) * 1970-09-15 1973-03-27 American Home Prod 4,10-(methaniminomethano phenanthrene derivatives
ZA73988B (en) * 1972-03-10 1973-10-31 Hoffmann La Roche Morphinan derivatives
US3914233A (en) * 1972-10-20 1975-10-21 Hoffmann La Roche 4-Hydroxy-N-substituted morphinan derivatives

Also Published As

Publication number Publication date
PH18458A (en) 1985-07-18
JPS5888364A (ja) 1983-05-26
ES8506635A1 (es) 1985-08-01
MC1490A1 (fr) 1983-09-12
ES517222A0 (es) 1984-12-01
ES8500948A1 (es) 1984-12-01
EP0079556A3 (de) 1983-08-24
HU187425B (en) 1986-01-28
NZ202404A (en) 1985-11-08
NO823707L (no) 1983-05-10
CA1195324A (en) 1985-10-15
GR78317B (es) 1984-09-26
AU9027682A (en) 1983-05-19
KR840002357A (ko) 1984-06-25
FI823824L (fi) 1983-05-10
FI823824A7 (fi) 1983-05-10
PT75815B (en) 1986-01-21
ZA827905B (en) 1983-08-31
DK491582A (da) 1983-05-10
US4374139A (en) 1983-02-15
FI823824A0 (fi) 1982-11-08
IL67180A0 (en) 1983-03-31
PT75815A (en) 1982-12-01
EP0079556A2 (de) 1983-05-25

Similar Documents

Publication Publication Date Title
ES517542A0 (es) Un procedimiento para la preparacion de derivados de 3-hidroxi-ml-236-b.
ES504103A0 (es) Un procedimiento para la preparacion de derivados de hidan- toina
ES502994A0 (es) Un procedimiento para la preparacion de derivados de pirazo-lopiridacina
ES502792A0 (es) Un procedimiento para la preparacion de derivados de imida- zol
ES499559A0 (es) Un procedimiento para la preparacion de derivados de pirrol
ES514264A0 (es) Un procedimiento para la preparacion de derivados de tiazolidi-nilalquilen-piperazinas.
ES517222A0 (es) Un procedimiento para la preparacion de derivados de acilmorrfinano.
ES524922A0 (es) Un procedimiento para la preparacion de nuevos derivados de 3-amino-pregn-5-eno
ES512880A0 (es) Un procedimiento para la preparacion de derivados de 4-anilino-pirimidina.
ES509437A0 (es) Un procedimiento para la preparacion de derivados carbapenen-2-tio-sustituidos.
ES524399A0 (es) Un procedimiento para la preparacion de derivados de milbenicina d
ES537467A0 (es) Un procedimiento para la preparacion de nuevas benzamidas
ES513880A0 (es) Un procedimiento para la preparacion de derivados de triazolurea.
ES536982A0 (es) Un procedimiento para la preparacion de un derivado de carbostirilo
ES515655A0 (es) Un procedimiento para la preparacion de derivados de benzotiazolina.
ES510611A0 (es) Un procedimiento para la preparacion de derivados de desoxiuridina.
ES513967A0 (es) Un procedimiento para la preparacion de derivados de etanola-mina.
ES518347A0 (es) Un procedimiento para la preparacion de derivados de desoxiuridina
ES515988A0 (es) Un procedimiento para la preparacion de nuevos derivados bencilicos trisustituidos
ES526149A0 (es) Un procedimiento para la preparacion de derivados de espirotiazolidinil-piperazina
ES540341A0 (es) Un procedimiento para la preparacion de derivados de piperi-dina
ES500911A0 (es) Un procedimiento para la preparacion de derivados de ergoli-na
ES527804A0 (es) Un procedimiento para la preparacion de derivados de oxacefalosporina
ES508775A0 (es) Un procedimiento para la preparacion de derivados de ciclo- hepteno.
ES498145A0 (es) Un procedimiento para la preparacion de derivados de metoxi-cefalosporinas